^
Association details:
| Biomarker: | ETV6-NTRK3 fusion |
|---|---|
| Cancer: | Fibrosarcoma |
| Drug: | vincristine (Tubulin polymerization inhibitor) + dactinomycin (Topoisomerase II inhibitor, RNA synthesis inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas
Excerpt:
The patient was a boy aged 5 months at the time of enrollment with an ETV6‐NTRK3 fusion, localized, infantile fibrosarcoma arising in the soft tissues of the forearm. He received vincristine and actinomycin D for 2 cycles and experienced disease progression.
DOI:
10.1002/cncr.31701
Trial ID:
